These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 15747747)
1. Von Hippel-Lindau gene deletion and expression of hypoxia-inducible factor and ubiquitin in optic nerve hemangioma. Chan CC; Lee YS; Zhuang Z; Hackett J; Chew EY Trans Am Ophthalmol Soc; 2004; 102():75-9; discussion 79-81. PubMed ID: 15747747 [TBL] [Abstract][Full Text] [Related]
2. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720 [TBL] [Abstract][Full Text] [Related]
3. Endolymphatic sac tumors in patients with and without von Hippel-Lindau disease: the role of genetic mutation, von Hippel-Lindau protein, and hypoxia inducible factor-1alpha expression. Jensen RL; Gillespie D; House P; Layfield L; Shelton C J Neurosurg; 2004 Mar; 100(3):488-97. PubMed ID: 15035285 [TBL] [Abstract][Full Text] [Related]
4. Expression of HIF-1 and ubiquitin in conventional renal cell carcinoma: relationship to mutations of the von Hippel-Lindau tumor suppressor gene. Hughson MD; He Z; Liu S; Coleman J; Shingleton WB Cancer Genet Cytogenet; 2003 Jun; 143(2):145-53. PubMed ID: 12781449 [TBL] [Abstract][Full Text] [Related]
5. VHL gene deletion and enhanced VEGF gene expression detected in the stromal cells of retinal angioma. Chan CC; Vortmeyer AO; Chew EY; Green WR; Matteson DM; Shen DF; Linehan WM; Lubensky IA; Zhuang Z Arch Ophthalmol; 1999 May; 117(5):625-30. PubMed ID: 10326959 [TBL] [Abstract][Full Text] [Related]
6. von Hippel-Lindau tumor suppressor: not only HIF's executioner. Czyzyk-Krzeska MF; Meller J Trends Mol Med; 2004 Apr; 10(4):146-9. PubMed ID: 15162797 [TBL] [Abstract][Full Text] [Related]
7. Molecular cloning and characterization of the von Hippel-Lindau-like protein. Qi H; Gervais ML; Li W; DeCaprio JA; Challis JR; Ohh M Mol Cancer Res; 2004 Jan; 2(1):43-52. PubMed ID: 14757845 [TBL] [Abstract][Full Text] [Related]
8. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hoffman MA; Ohh M; Yang H; Klco JM; Ivan M; Kaelin WG Hum Mol Genet; 2001 May; 10(10):1019-27. PubMed ID: 11331612 [TBL] [Abstract][Full Text] [Related]
9. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. Tanimoto K; Makino Y; Pereira T; Poellinger L EMBO J; 2000 Aug; 19(16):4298-309. PubMed ID: 10944113 [TBL] [Abstract][Full Text] [Related]
10. Inactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von Hippel-Lindau disease-associated vascular tumors in mice. Rankin EB; Higgins DF; Walisser JA; Johnson RS; Bradfield CA; Haase VH Mol Cell Biol; 2005 Apr; 25(8):3163-72. PubMed ID: 15798202 [TBL] [Abstract][Full Text] [Related]
11. The von Hippel-Lindau tumor suppressor gene. Kondo K; Kaelin WG Exp Cell Res; 2001 Mar; 264(1):117-25. PubMed ID: 11237528 [TBL] [Abstract][Full Text] [Related]
12. Specific oncolytic effect of a new hypoxia-inducible factor-dependent replicative adenovirus on von Hippel-Lindau-defective renal cell carcinomas. Cuevas Y; Hernández-Alcoceba R; Aragones J; Naranjo-Suárez S; Castellanos MC; Esteban MA; Martín-Puig S; Landazuri MO; del Peso L Cancer Res; 2003 Oct; 63(20):6877-84. PubMed ID: 14583486 [TBL] [Abstract][Full Text] [Related]
13. Molecular targets from VHL studies into the oxygen-sensing pathway. Maynard MA; Ohh M Curr Cancer Drug Targets; 2005 Aug; 5(5):345-56. PubMed ID: 16101382 [TBL] [Abstract][Full Text] [Related]
14. Role of exon 2-encoded beta -domain of the von Hippel-Lindau tumor suppressor protein. Bonicalzi ME; Groulx I; de Paulsen N ; Lee S J Biol Chem; 2001 Jan; 276(2):1407-16. PubMed ID: 11024059 [TBL] [Abstract][Full Text] [Related]
15. Oxygen-dependent ubiquitination and degradation of hypoxia-inducible factor requires nuclear-cytoplasmic trafficking of the von Hippel-Lindau tumor suppressor protein. Groulx I; Lee S Mol Cell Biol; 2002 Aug; 22(15):5319-36. PubMed ID: 12101228 [TBL] [Abstract][Full Text] [Related]
16. Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer. Maynard MA; Ohh M Am J Nephrol; 2004; 24(1):1-13. PubMed ID: 14654728 [TBL] [Abstract][Full Text] [Related]
17. Expression of fibronectin and HIF-1alpha in renal cell carcinomas: relationship to von Hippel-Lindau gene inactivation. He Z; Liu S; Guo M; Mao J; Hughson MD Cancer Genet Cytogenet; 2004 Jul; 152(2):89-94. PubMed ID: 15262424 [TBL] [Abstract][Full Text] [Related]
18. Identification of novel VHL target genes and relationship to hypoxic response pathways. Maina EN; Morris MR; Zatyka M; Raval RR; Banks RE; Richards FM; Johnson CM; Maher ER Oncogene; 2005 Jun; 24(28):4549-58. PubMed ID: 15824735 [TBL] [Abstract][Full Text] [Related]
19. Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor. Baba M; Hirai S; Yamada-Okabe H; Hamada K; Tabuchi H; Kobayashi K; Kondo K; Yoshida M; Yamashita A; Kishida T; Nakaigawa N; Nagashima Y; Kubota Y; Yao M; Ohno S Oncogene; 2003 May; 22(18):2728-38. PubMed ID: 12743597 [TBL] [Abstract][Full Text] [Related]
20. Renal cell carcinoma- and pheochromocytoma-specific altered gene expression profiles in VHL mutant clones. Tsuchiya MI; Okuda H; Takaki Y; Baba M; Hirai S; Ohno S; Shuin T Oncol Rep; 2005 Jun; 13(6):1033-41. PubMed ID: 15870918 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]